(E)-3-((((1-(2-chloro-4-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)phenyl)ethylidene)amino)oxy)methyl)-4-cyanobenzoic acid

ID: ALA5279076

Chembl Id: CHEMBL5279076

Max Phase: Preclinical

Molecular Formula: C31H23ClF3N3O6

Molecular Weight: 625.99

Associated Items:

Names and Identifiers

Canonical SMILES:  C/C(=N\OCc1cc(C(=O)O)ccc1C#N)c1ccc(OCc2c(-c3ccccc3OC(F)(F)F)noc2C2CC2)cc1Cl

Standard InChI:  InChI=1S/C31H23ClF3N3O6/c1-17(37-42-15-21-12-19(30(39)40)8-9-20(21)14-36)23-11-10-22(13-26(23)32)41-16-25-28(38-44-29(25)18-6-7-18)24-4-2-3-5-27(24)43-31(33,34)35/h2-5,8-13,18H,6-7,15-16H2,1H3,(H,39,40)/b37-17+

Standard InChI Key:  YQSSHFJUFMLIMK-YSYOEVFLSA-N

Alternative Forms

  1. Parent:

    ALA5279076

    ---

Associated Targets(Human)

NR1H4 Tclin Bile acid receptor FXR (6228 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GPBAR1 Tchem G-protein coupled bile acid receptor 1 (1723 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Nr1h4 Bile acid receptor (142 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 625.99Molecular Weight (Monoisotopic): 625.1227AlogP: 7.86#Rotatable Bonds: 11
Polar Surface Area: 127.17Molecular Species: ACIDHBA: 8HBD: 1
#RO5 Violations: 2HBA (Lipinski): 9HBD (Lipinski): 1#RO5 Violations (Lipinski): 2
CX Acidic pKa: 3.50CX Basic pKa: 1.73CX LogP: 7.63CX LogD: 4.40
Aromatic Rings: 4Heavy Atoms: 44QED Weighted: 0.13Np Likeness Score: -1.12

References

1. Tang X, Ning M, Ye Y, Gu Y, Yan H, Leng Y, Shen J..  (2021)  Discovery of novel ketoxime ether derivatives with potent FXR agonistic activity, oral effectiveness and high liver/blood ratio.,  43  [PMID:34256254] [10.1016/j.bmc.2021.116280]

Source